GENOMINE is a company focused on the discovery, development and commercialization of biomarkers and diagnostic kits for early detection of cancers.
GENOMINE has been working on a full range of services to support various proteome-related researches from separation and identification of proteins to analysis of post-translational modifications such as phosphorylation and glycosylation. We have well equipped proteomics core facility and our staff scientists are experienced proteomics professionals.

GENOMINE is dedicated to the development of in vitro antibody-based assays for a select group of cancers that are difficult to accurately diagnose without resorting to expensive and invasive methods like biopsies, resulting in numerous, unnecessary procedures at a considerable cost to patients and the health care industry.

Through a long term of collaborative research with medical doctors in cancer hospitals, we successfully discovered novel biomarkers for kidney cancer and developed into immunoassay format to meet clinical test standard.  It showed a high sensitivity and specificity in a trial of patients with kidney cancer.
GENOMINE currently has 7 cancer diagnostic programs under development designed to assist with the early detection of cancer, thereby reducing suffering, saving lives and cutting healthcare costs.